Clinical application of Clostridium botulinum type A neurotoxin purified by a simple procedure for patients with urinary incontinence caused by refractory destrusor overactivity.
Type A neurotoxin of Clostridium botulinum was purified by a simple procedure using a lactose gel column. This procedure was previously reported for type B neurotoxin. Hemagglutinin-positive toxins (19S and 16S) were bound to the column under acid conditions, and the neurotoxin alone was dissociated from these hemagglutinin-positive toxins by changing the pH of the column to an alkaline condition. The toxicity of this purified toxin preparation was retained for at least 1 year at -30 degrees C by supplementing it with either 0.1% albumin or 0.05% albumin plus 1% trehalose. This preparation was used to treat 18 patients with urinary incontinence caused by refractory idiopathic and neurogenic detrusor overactivity; 16 of the patients showed excellent improvement. Improvements started within 1 week after injection in most cases and lasted 3-12 months [corrected]
Lee
Jae-Chul
JC
Department of Bacteriology, Okayama University Medical School, Okayama, Japan.
Yokoyama
Teruhiko
T
Hwang
Hyun-Jung
HJ
Arimitsu
Hideyuki
H
Yamamoto
Yumiko
Y
Kawasaki
Makiko
M
Takigawa
Tomoko
T
Takeshi
Kouichi
K
Nishikawa
Atsushi
A
Kumon
Hiromi
H
Oguma
Keiji
K
D000328:Adult; D000368:Aged; D000818:Animals; D019274:Botulinum Toxins, Type A / Q000302:isolation & purification / Q000627:therapeutic use*; D002460:Cell Line; D004355:Drug Stability; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009498:Neurotoxins / Q000627:therapeutic use*; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D014549:Urinary Incontinence / Q000188:drug therapy* / Q000209:etiology
D009498:Neurotoxins; D019274:Botulinum Toxins, Type A